Please use this identifier to cite or link to this item:
|Title:||Willingness-to-pay and preferences for warfarin pharmacogenetic testing in Chinese warfarin patients and the Chinese general public||Authors:||Chan, S.L.
Wen Low, J.J.
discrete choice experiment
|Issue Date:||2013||Citation:||Chan, S.L., Wen Low, J.J., Lim, Y.W., Finkelstein, E., Farooqui, M.A., Chia, K.S., Wee, H.L. (2013). Willingness-to-pay and preferences for warfarin pharmacogenetic testing in Chinese warfarin patients and the Chinese general public. Personalized Medicine 10 (2) : 127-137. ScholarBank@NUS Repository. https://doi.org/10.2217/pme.12.124||Abstract:||Aim: Genetic factors have been found to affect warfarin maintenance dose and a key factor for the successful clinical implementation of warfarin pharmacogenetic testing (WPGT) is economic sustainability. We aimed to estimate the willingness-to-pay (WTP) and preferences for WPGT in Singaporean Chinese subjects. Methods & subjects: A total of 197 warfarin patients and 187 members of the public completed a questionnaire. The discrete choice methodology was used and the choice model was estimated using hierarchical Bayes. Marginal WTP, attribute importance and WTP for three hypothetical WPGTs were calculated from the estimated utilities. Results: Both patients and the public placed most emphasis on side effects, followed by cost, number of International Normalized Ratio tests and 'nature of test. WTP for WPGT ranged from S160 to S730. Conclusion: WPGTs are likely to be economically sustainable. © 2013 Future Medicine Ltd.||Source Title:||Personalized Medicine||URI:||http://scholarbank.nus.edu.sg/handle/10635/53260||ISSN:||17410541||DOI:||10.2217/pme.12.124|
|Appears in Collections:||Staff Publications|
Show full item record
Files in This Item:
There are no files associated with this item.
checked on Mar 2, 2021
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.